Skip to contentI
Insight Molecular Diagnostics Inc.
I
IMDXInsight Molecular Diagnostics Inc. Q1 2021 · 10-Q
Revenue$1.12M$1.12M+6,925.0% vs Q1 2020 Net Income-$3.92M-$3.92MN/M vs Q1 2020 EPS Diluted-$0.05-$0.05N/M vs Q1 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Insight Molecular Diagnostics Inc. · CIK 1642380 · Engraved from SEC EDGAR
Operating Cash Flow-$9,835,000N/M Free Cash Flowderived-$10,677,000N/M Margins · derivedGross margin7.0%
Operating margin-1010.7%+51683.1 pt vs Q1 2020
Net margin-348.7%+47976.3 pt vs Q1 2020
ended Mar 31, 2021 · filed May 17, 2021 · 47 d after period end